highest dose of glp-1 Full Retatrutide data just presented at the ADA conference to a packed room. Just a refresher, it is a GLP-1/GIP/Glucagon agonist. It hits all three receptors as opposed to semaglutide which hits ​"Triple-Hormone" Drug Shows Record Weight

(2) If an ACO is determined to be experienced with performance-based risk Medicare ACO initiatives, the ACO may enter either the BASIC track Level E under paragraph (a)(4)(i)(A)( 5 ) of this section for all performance years of the agreement period, or the ENHANCED track under paragraph (a)(3) of this section, except as otherwise specified in paragraph (h)(3) of this section

Promotional segments show that this weight loss medication is to be targeted towards individuals who are obese, overweight and have type 2 diabetes, sleep apnea, hypertension, knee osteoarthritis, cholesterol concerns, and/or dementia

Approximately 44 per cent of users reported at least one side effect, with gastrointestinal symptoms such as nausea and diarrhoea predominating

The key is designing the cost-share to discourage casual use while keeping the medication affordable for employees who are clinically committed to treatment